AI-powered mobile app to help breast cancer patients manage chemotherapy symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial tests an AI-supported mobile application for symptom management, self-efficacy, and quality of life in women with breast cancer starting chemotherapy. Participants are assigned to use the app or receive standard care, with outcomes measured during their chemotherapy course. The study is conducted at two Turkish centers and targets first-time chemotherapy recipients with stage 0–III disease and good performance status. The intervention aims to improve symptom control, empower patients, and enhance overall well-being compared with usual care. Enrollment is limited to adults with Turkish literacy who own a smartphone and can use the app.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients aged 18 years and older.
* Diagnosed with breast cancer.
* Patients with Stage 0, I, II, or III breast cancer.
* Receiving chemotherapy for the first time.
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
* In a stable physical and psychological condition that does not interfere with participation in the study.
* Able to read and write in Turkish.
* Own a smartphone and have sufficient technological skills to use the mobile application.
* Willing to participate in the study and able to provide written informed consent.

Exclusion Criteria:

* Patients diagnosed with a primary cancer other than breast cancer.
* Patients with severe comorbid diseases.
* Patients receiving concurrent radiotherapy.
* Patients diagnosed with inflammatory breast cancer.
* Patients using luteinizing hormone-releasing hormone (LHRH) analogs.
* Patients with severe cognitive impairment or psychiatric disorders.
* Patients who do not have access to a mobile device or internet connection.
* Patients who do not have the skills necessary to use the mobile application.

Where it's running

• Ege University Hospital, Berna Türek Chemotherapy Center
  Izmir, İzmir, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Yasemin Yıldırım, Prof. Dr. — Ege University
• Study coordinator: Gökhan Sezgin, PhD Candidate
• Email: gokhan.sezgin95@gmail.com
• Phone: +00905363005966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.